<DOC>
	<DOCNO>NCT01253200</DOCNO>
	<brief_summary>The purpose BLOCk-CTI study evaluate safety effectiveness Blazer速 Open-Irrigated Ablation Catheter treatment sustain recurrent type 1 atrial flutter . This study compare outcomes patient treated Blazer速 Open-Irrigated Ablation Catheter outcomes patient treat open-irrigated radiofrequency ablation catheter receive FDA market approval treatment type 1 atrial flutter .</brief_summary>
	<brief_title>Clinical Evaluation Blazer速 Open-Irrigated Catheter Treatment Type 1 Atrial Flutter</brief_title>
	<detailed_description>The BLOCk-CTI study prospective , multicenter , single blind , 1:1 randomize study . The study design demonstrate safety effectiveness Blazer速 Open-Irrigated Ablation Catheter non-inferior safety effectiveness control catheter . In study , control catheter open-irrigated radiofrequency ablation catheter receive FDA market approval treatment type 1 atrial flutter .</detailed_description>
	<mesh_term>Atrial Flutter</mesh_term>
	<mesh_term>Acifluorfen</mesh_term>
	<criteria>At least 1 documented episode type 1 atrial flutter 180 day ( 6 month ) precede enrollment document 12lead ECG , Holter monitor , rhythm strip , transtelephonic monitor Patients clinically indicated catheter ablation Patients receive oral antiarrhythmic drug therapy ( class I class III ) tachyarrhythmia type 1 atrial flutter must control antiarrhythmic drug minimum 30 day prior enrollment . If type 1 atrial flutter document prior development tachyarrhythmias , 30day period require . Age 18 , legal age give inform consent specific state national law Patients competent willing provide write informed consent participate study agree comply followup visit evaluation Any prior right atrial cavotricuspid isthmus ablation cardiac ablation nonatrial flutter arrhythmia within 90 day prior enrollment Cardiac surgery within 90 day prior enrollment Myocardial infarction within 60 day prior enrollment Current unstable angina Patients antiarrhythmic drug ( class I class III ) prescribe treatment type 1 atrial flutter stop day procedure Patients regularly prescribe amiodarone within 120 day ( 4 month ) prior enrollment Documented atrial ventricular tumor , clot , thrombus , know clot disorder within 90 day prior enrollment Implantation permanent lead implantable device right atrium within 90 day prior enrollment Direct remedial cause atrial flutter ( e.g . thyroid disease , pericarditis , pulmonary embolic disease ) Atypical scarbased flutter Patients New York Heart Association Class III time enrollment New York Heart Association Class IV heart failure within 90 day prior enrollment Patients ejection fraction le 30 % within 90 day prior enrollment Clinically significant structural heart disease ( include tricuspid valve regurgitation , tricuspid valve stenosis , tricuspid valve replacement , Ebstein 's anomaly , congenital heart disease ) would preclude catheter introduction placement , determine Investigator Any cerebral ischemic event ( include transient ischemic attack ) within 180 day prior enrollment Contraindication anticoagulation therapy base upon publish guideline Creatinine great 2.5 mg/dl creatinine clearance le 30 mL/min within 90 day prior enrollment Any significant uncontrolled unstable medical condition ( e.g . sepsis , acute metabolic illness ) Enrolled concurrent study without BSC write approval Women pregnant plan become pregnant within course participation investigation Life expectancy less equal 2 year ( 730 day ) per physician opinion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Type 1 Atrial Flutter</keyword>
	<keyword>Typical Atrial Flutter</keyword>
	<keyword>Arrhythmias , Cardiac</keyword>
	<keyword>Heart Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
</DOC>